Xenon Pharmaceuticals
Update in progressXENE (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company that discovers and develops therapies for neurological and psychiatric disorders. Its lead candidate Azetukalner is a Kv7 potassium channel opener in Phase 3 for epilepsy and may treat major depressive disorder and bipolar depression. Other programs include XEN1701 (sodium channel) and XEN1120 (Kv7) in early trials. It partners with Neurocrine for NBI-921355. Founded 1996, Burnaby, Canada.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationCanada
- CEOMr. Ian C. Mortimer C.M.A., CPA, M.B.A.
- Founded1996
- Employees358
- Websitewww.xenon-pharma.com
Identifiers
- ISINCA98420N1050
- FIGIBBG0073DM784
- CUSIP98420N105
- CIK0001582313